Decline is not inevitable.
A daily, evidence-graded view of everything moving in kidney research : the drugs that slow decline, the science of regeneration, and the mind-body work.
A study on hypotension risk in end-stage kidney disease patients found no new results
-
No new findings for hypotension risk in end-stage kidney disease patients
-
The study on hypotension risk is still ongoing with no new data reported
No new results were reported in this batch. The study on hypotension risk in end-stage kidney disease patients continues without new findings.
From Risk Identification to Risk Modification in Patients With End-Stage Renal Disease Undergoing Rotational Atherectomy.
A study of 10 patients with kidney disease and heart-related artery blockages was corrected. It found that using a rotating wire to clear arteries in the kidney-damaged group led to more heart attacks than the control group. This study was small: 10 patients, and results were measured over 6 months.
Urine and Plasma Extracellular Vesicle Analysis for Monitoring Renal Recovery after Acute Kidney Injury.
This study used urinary and plasma-derived vesicles to track kidney injury recovery in AKI patients. These vesicles reflect the health of renal cells, but this small study cannot confirm if they predict long-term kidney function.
Arterial Stiffness in Children and Young People With Hypertension and Chronic Kidney Disease
This trial looks at arterial stiffness (hardening of arteries) in children and young people with kidney disease. Arterial stiffness is a marker for cardiovascular risk, but this study's results are not yet available.
Impact of Acute Kidney Injury on Hospitalization Outcomes in Patients with Chronic Kidney Disease Undergoing Cardiac Procedures with Cardiopulmonary Bypass in the United States.
Acute kidney injury (AKI) after cardiac surgery may cause permanent damage. This study looks at risk in patients with pre-existing kidney disease.
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
This is an extension study for patients who completed a previous trial of zigakibart. It will monitor long-term safety in adults with IgA nephropathy.
68Ga-FAPI-04 PET/CT Findings in Primary Hyperoxaluria Type 1.
This case report shows that FAPI-PET/CT can detect active fibrosis (scarring) in patients with primary hyperoxaluria type 1. This may help identify patients at risk for kidney damage from oxalate crystals.
Concomitant Aortic Valve Neocuspidization and Resection of a Cardiac Calcified Amorphous Tumor in a Hemodialysis Patient: A Case Report.
This case report describes two cardiac masses in a patient on hemodialysis: one mobile and one fixed. These lesions carry an embolic risk (risk of stroke or other emboli).
Psychological resilience trajectories and baseline factors associated with trajectory membership among patients newly initiating maintenance hemodialysis: A multicenter longitudinal study.
This study followed 693 people through their first 6 months on dialysis. It tracked how their ability to bounce back mentally, called resilience, changed over time. People fell into a few different patterns, and things like their starting state of mind were linked to which pattern they followed. This shows links only, not cause, and no treatment was tested.
Combination therapy of RAS inhibition and glucagon-like peptide-1 receptor agonist improves a marker of kidney fibrosis in people with type 2 diabetes.
Researchers combined two drugs in people with type 2 diabetes: a blood pressure drug (a RAS inhibitor) and a GLP-1 drug. They measured a substance in the urine that tracks kidney scarring, called C3M. The combination lowered this marker, which may hint at less scarring. But this is only a marker, not proof the kidneys were protected, and it shows a link rather than cause.
Nephrocalcinosis Following Roux-en-Y Gastric Bypass Secondary to Suspected Enteric Hyperoxaluria: A Case Report.
Gastric bypass surgery may lead to calcium oxalate deposits in the kidney. This case report discusses risk factors for this condition.
Pendrin inhibitor PDSinh-C01 reverses salt-sensitive hypertension and metabolic acidosis in the 5/6 nephrectomy rat model.
In rats bred to have kidney disease, a drug called PDSinh-C01 lowered salt-driven high blood pressure and corrected acid buildup in the blood. The drug blocks a kidney protein called pendrin. This was done in animals, not people yet. It is an early sign the target may be worth testing.
Erastin-sensitive VDAC2 contributes to time-course peritoneal fibrosis via ferroptosis signaling induction.
In the lab, scientists studied why the lining used in peritoneal dialysis gets scarred over time. They found a form of cell death called ferroptosis, driven by a channel named VDAC2, may add to this scarring. This work was done in cells and cell data, not in people yet. It points to a possible target for future treatment.
Too sweet to be true? Prophylactic SGLT2 inhibitors before cardiac surgery — NephJC
This is an online journal club post discussing a new trial. The trial tested dapagliflozin, an SGLT2 drug, to prevent sudden kidney injury after heart surgery. The post is a discussion, not the trial results themselves, so there are no findings to report here.
Cost-effectiveness analysis comparison of etelcalcetide, paricalcitol, and cinacalcet for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
This study compared the cost and value of three drugs for overactive parathyroid glands, a common problem in kidney disease. It used a computer model of the Chinese health system over one year, not a new trial in patients. It reports which drug may give the best value for the money. There are no new results about how patients actually did.